Jakavi 10mg Tablet contains Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor used primarily in the treatment of myeloproliferative disorders such as intermediate or high-risk myelofibrosis and polycythemia vera in patients who are resistant or intolerant to hydroxyurea. By inhibiting JAK1 and JAK2 enzymes, Jakavi modulates the aberrant signaling pathways involved in hematopoiesis and inflammatory processes, thereby reducing splenomegaly and alleviating disease-related symptoms such as fatigue, night sweats, and pruritus. The recommended dosage of Jakavi 10mg varies based on the patient’s condition, hematologic parameters, and response to therapy, with dose adjustments made to minimize adverse effects. Common side effects include thrombocytopenia, anemia, neutropenia, dizziness, and headache, necessitating regular monitoring of blood counts during treatment. Jakavi should be used with caution in patients with hepatic or renal impairment and is contraindicated in those with known hypersensitivity to Ruxolitinib or its excipients. Due to its immunosuppressive effects, patients should be monitored for infections and advised accordingly. Jakavi 10mg Tablet offers a targeted therapeutic option that improves quality of life and clinical outcomes in patients with specific myeloproliferative neoplasms.